---
title: "Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit"
date: "2025-02-11 08:13:38"
summary: "blackdovfx/iStock via Getty Images  Sangamo Therapeutics (NASDAQ:SGMO) leverages zinc finger proteins (ZFPs) and AAV capsid delivery (engineered for blood-brain barrier penetration) to develop therapeutics for genetic diseases. Sangamo is targeting indications like idiopathic small fiber neuropathy, prion disease, Fabry disease, and hemophilia A. The latter features"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/479454756/image_479454756.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Abstract DNA.](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/479454756/image_479454756.jpg?io=getty-c-w750) 



blackdovfx/iStock via Getty Images





**Sangamo Therapeutics** (NASDAQ:[SGMO](https://seekingalpha.com/symbol/SGMO "Sangamo Therapeutics, Inc.")) leverages zinc finger proteins (ZFPs) and AAV capsid delivery (engineered for blood-brain barrier penetration) to develop therapeutics for genetic diseases. Sangamo is targeting indications like idiopathic small fiber neuropathy, prion disease, Fabry disease, and hemophilia A. The latter features

[seekalpha_articles](https://seekingalpha.com/article/4756823-sangamo-therapeutics-challenging-road-ahead-after-pfizer-exit)
